Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Adverse events, total · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in adverse events, total compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 0.86 [0.62, 1.19]
1 study · 64 participants
Low

Serious adverse events · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in serious adverse events compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 0.47 [0.13, 1.72]
1 study · 64 participants
Low